Etoricoxib-induced erythema-multiforme-like eruption.

Aged; Arthritis/drug therapy; Cyclooxygenase 2 Inhibitors/adverse effects; Drug Eruptions/etiology/pathology; Erythema Multiforme/chemically induced/pathology; Humans; Male; Pyridines/adverse effects; Skin/pathology; Sulfones/adverse effects

Abstract :

[en] Etoricoxib is a new, highly selective cyclooxygenase (COX) 2 inhibitor, reported to have an increased cutaneous and systemic safety profile compared to the previous COX-2 inhibitors, including celecoxib, rofecoxib and valdecoxib. To the best of our knowledge, the present case of etoricoxib-induced erythema-multiforme-like eruption is the first reported in the literature.

Disciplines :

Dermatology

Author, co-author :

Thirion, Laurence; Université de Liège - ULiège > Département de pharmacie > Département de pharmacie

Nikkels, Arjen ; Centre Hospitalier Universitaire de Liège - CHU > Dermatologie

Pierard, Gérald ; Centre Hospitalier Universitaire de Liège - CHU > Dermatopathologie

Language :

English

Title :

Etoricoxib-induced erythema-multiforme-like eruption.

Publication date :

07 November 2007

Journal title :

Dermatology

ISSN :

1018-8665

eISSN :

1421-9832

Publisher :

S. Karger, Basel, Switzerland

Volume :

216

Issue :

Pages :

227-228

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 16 December 2008

Statistics

Number of views

122 (15 by ULiège)

Number of downloads

2 (2 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

Bibliography

Woodfork KA, Dyke KV: Anti-inflammatory and antirheumatic drugs; in Craig DR, Stitzel RE (eds): Modern Pharmacology with Clinical Applications, ed 6. Philadelphia, Lippincott, Williams & Wilkins, 2004, pp 423-439.
Mandal SP: Etoricoxib - a new, potent and highly selective COX-2 inhibitor. JAMA India 2004;3:79-82.
Mahajan A, Sharma R: COX-2 selective nonsteroidal anti-inflammatory drugs: current status. J Assoc Physicians India 2005;53:200-204.
Sanchez-Borges M, Caballero-Fonseca F, Carpiles-Hulett A: Safety of etoricoxib, a new cyclooxygenase 2 inhibitor, in patients with nonsteroidal anti-inflammatory drug-induced urticaria and angioedema. Ann Allergy Asthma Immunol 2005;95:154-158.
Quialte J, Delgado J, Sanez de San Pedro B, et al: Safety of the new selective cyclooxygenase type 2 inhibitors rofecoxib and celecoxib in patients with anaphylactoid reactions to nonsteroidal anti-inflammatory drugs. Ann Allergy Asthma Immunol 2004;93:360-364.
Sanchez-Borges M, Capriles-Hulett A, Caballero-Fonseca F, Perez CR: Tolerability to new COX-2 inhibitors in NSAID-sensitive patients with cutaneous reactions. Ann Allergy Asthma Immunol 2001;87:201-204.
Scheider F, Meziani F, Chartier C, Alt M, Jaeger A: Fatal allergic vasculitis associated with celecoxib. Lancet 2002;359:852-853.
Goeschke B, Braathen LR: Acute generalized exanthematic pustulosis: a case and an overview of side effects affecting the skin caused by celecoxib and other COX-2 inhibitors reported so far. Dermatology 2004;209:53-56.
Layton D, Marshall V, Boshier A, Friedmann P, Shakir SA: Serious skin reactions and selective Cox-2 inhibitors: a case series from prescription-event monitoring in England. Drug Saf 2006;29:687-696.
D'Martina S, Vesta KS, Ripley TL: Etoricoxib: a highly selective COX-2 inhibitor. Ann Pharmacother 2005;39:854-862.
Leclercq P, Malaise MG: Le médicament du mois: etoricoxib (Arcoxia®). Rev Méd Liège 2004;59:345-349.